* A new study suggests that Maintenance Docetaxel increases significantly progression survival: "Single-dose monthly maintenance treatments for a total of up to 12 months were offered to patients who had a complete response. Median time to recurrence was 39.3 months in responders treated with maintenance docetaxel, compared with 19 months in those who did not receive maintenance therapy.<sup>"(Medscape)

*READ IT1</sup>

"Radiolabeled Small Molecules Show Promise in Prostate Cancer Early Detection

By Zach Hartman | March 20, 2013

---

Radiolabeled small molecules targeting prostate-specific membrane antigen (PSMA) are well-tolerated tools for detection of metastatic prostate cancer, according to data published in the March 2013 issue of the Journal of Nuclear Medicine."

*Lymphoseek FDA approved for detection of metastatic disease involving the lymph nodes for Breast cancers and Melanoma!

Early detection of Lung Cancer

LUNG CANCER EARLY DETECTION:

CRBCM IS SEEKING FUNDING FOR A STUDY TO SEE WHETHER CURRENT MOLECULAR TESTING COULD DETECT EARLY LUNG CANCER IN SELECTED GROUPS OF HEAVY SMOKERS.  WE PLAN TO SELECT 150 HEAVY SMOKERS (HISTORY OF 60 PACK A YEAR).
OBTAIN SEQUENCIAL SERUM LEVELS OF E-CADHERIN, METALLOPROTEINASE, AND TUMOR GROWTH FACTOR BETA (EVERY 3 MONTHS FOR 1 YEAR).  A PET SCAN WILL BE OBTAINED AT DAY 1 AND DAY 365.  SELECTED INDIVIDUALS  WILL BE OBSERVED FOR 3-5 YEARS THERE AFTER WITH YEARLY CHECK OF MARKERS AFTER THE FIRST YEAR.

ALTHOUGH PET FINDINGS ARE CRITICAL FOR OUR EVALUATION, WHAT WE ARE CONCENTRATING ON IS TO SEE WHETHER THESE "TUMOR MARKERS" FOLLOWED SEQUENTIALLY COULD PREDICT LUNG CANCER IN HEAVY SMOKERS.

IT WOULD BE INTERESTING TO SEE THE LEVELS OF THESE MARKERS ON PATIENTS WITH INCIDENTAL POSITIVE PET FINDINGS.  ANOTHER COROLLARY MEASUREMENT WILL SCREEN FOR ANA AND RHEUMATOID FACTOR TO SEE WHETHER COEXISTING AUTOIMMUNE DISEASES AFFECT THE PATTERN OF THESE MARKERS, PARTICULARLY THE TGF.
SHOULD THESE FINDINGS BE SIGNIFICANT, A TRIPLE KIT COULD BE DEVELOPED FOR EARLY DETECTION OF LUNG CANCER.

Looking into the role of Ciprofloxacin in cancer cell apoptosis

Colorectal cancer (CRC) is the second most commonly diagnosed cancer and the second leading cause of cancer mortality in the United States among cancers that affect both men and women.
Screening lowers colorectal cancer (CRC) incidence and mortality. CRC is preventable through the removal of premalignant polyps and is curable if diagnosed early. Increased CRC screening and reduced CRC incidence and mortality are among the Healthy People 2020 objectives.
What if CRC could be prevented, at least to a certain degree?

Here an interesting finding that will need further research and require validation in the endeavor to prevent cancer, CRC being a priority target:
Pulm Pharmacol Ther. 2010 Oct;23(5):373-5. Epub 2010 Mar 6.
"Ciprofloxacin can significantly affect eukaryotic cells including human cancer cells. Its bactericidal action relay on inhibition of topoisomerase II, enzyme responsible for alterations in 3D structure of DNA during replication, transcription and chromatin condensation. Thanks to that, ciprofloxacin can induce cell cycle arrest and apoptosis of cancer cells."

The stakes are high. Lives can be saved. The cost to society for premature death from CRC are too high - we need to become even more proactive than with screening alone.
The medical and societal costs of CRC are substantial. Estimated direct medical costs for CRC care in 2010 were $14 billion, with projected costs of up to $20 billion by 2020 (13). In 2006, estimated lost productivity costs for persons who died from CRC were $15.3 billion (14). This equals $288,468 of lost productivity per CRC death in 2006 (14). Screening costs per person vary by test. The lifetime (age 50--80 years) average per person cost of screening ranges from $71 per person for guaiac-based FOBT to $1,397 per person for colonoscopy (15).

Letter to President Obama

Letter to President Barack Obama (D): Contact Your Federal Officials

President Barack Obama (D-US) 1st term · More Letters to   President Obama · Search All   Letters See Vice President See First Lady Letters To Leaders All messages are published with permission of the sender. The general topic of this message is Women's Issues: Subject: Contact Your Federal Officials To: President Barack Obama Sen. John Cornyn Rep. Silvestre Reyes Sen. Kay Bailey Hutchison May 21, 2012  Coalition for the Reversal of Breast Cancer Mortality in African American Women: Dear Mr President, Dear Senators, Dear Representatives, the Coalition I represent would like to call your attention upon the following issue: Of the estimated 6,040 annual deaths in the African American community because of Breast Cancer, up to 3,000 could be prevented. My own mother died of breast cancer and I promised her that I will do something on her behalf before I pass on. I would be glad to forward the full set of statistical and scientific data that supports our findings. With the CRBCM we are now calling for a formal acknowledgement of this issue and a promise that a 10-year priority program should seek the reversal of this mortality of innocent African American women. Let us invest in saving lives at home. 3,000 African American women will die this year alone and effective action is urgently needed. The reasons why African American Women are still today missing out on appropriate and timely screening for breast cancer and early intervention have been researched, analyzed and published. No tangible measures, however, have been suggested to bridge the gap between existing resources, the wealth of scientific and socio-economic knowledge and the effective communication with the African American women who keep missing out on this specific type of time sensitive health care. In the evolving history of breast cancer mortality, interventions by leaders have proven to be effective. Mammograms, the cessation of hormone replacement therapy, the discovery of the BRCA Mutation, all have proven effective in reducing mortality, and led to an adjustment of treatment guidelines. The next main action with the largest impact is to invest in interventions to curb the breast cancer mortality in African American women who take the brunt by their heavy share of reversible mortality. The present Coalition proposes an action plan to reach out to these women who live outside the traditional healthcare and social safety nets in our nation, so that they can finally benefit from the free breast cancer prevention programs that have been made available since 2000. The Coalition will also push for improved and specific breast cancer screening for this segment of the population and initiate further research into the specificity of the histology of breast cancer in African American women as it had been accomplished for the 1% of women of Ashkenazi Jewish descendence with the BRCA mutation and consequently modified guidelines. With advances in radiologic detection methods and genetics (the human genome is decoded) it is time to see the decrease of breast cancer mortality in African American women as a reachable and objective goal within 10 years. I am calling to your human side and compassion to pay closer attention to this priority problem. El Paso , TX